On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).The single-cell and spatial biology company reported quarterly sales of $165.02 million, down 10% year over year, beating the consensus of $159.39 million.Gross margin was 67% for the fourth quarter of 2024 compared to 63% a year ago, primarily due to product mix changes.10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million f ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Can ...

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25%. A quarter ago, it was expected that this life science technology company would post a loss of $0.34 per share when it actually produced a loss of $0.30, delivering a surprise of 11.76%.Over the last four quarters, the co ...

Financial Performance - For the year ended December 31, 2024, 10x Genomics, Inc. recognized revenues of $610.8 million[411]. - Revenue for the year ended December 31, 2024, was $610.785 million, a decrease of 1.5% from $618.727 million in 2023[416]. - Revenue from consumables increased to $493.432 million in 2024, compared to $479.553 million in 2023, driven by a rise in spatial consumables revenue[492]. - Net loss for 2024 was $182.627 million, an improvement from a net loss of $255.099 million in 2023, representing a 28.4% reduction[419]. - Net loss per share improved to $(1.52) in 2024 from $(2.18) in 2023[416]. - The company reported net cash provided by operating activities of $6.664 million in 2024, a significant improvement from a net cash used of $(15.197) million in 2023[424]. - The company’s total comprehensive loss for 2024 was $182.691 million, compared to $251.193 million in 2023, showing a reduction of approximately 27.3%[419]. Assets and Liabilities - As of December 31, 2024, total assets were $918.6 million, a decrease from $965.1 million in 2023[414]. - Cash and cash equivalents decreased to $344.1 million in 2024 from $359.3 million in 2023[414]. - Accounts receivable, net, decreased to $87.9 million in 2024 from $114.8 million in 2023[414]. - Total stockholders' equity decreased to $710.1 million in 2024 from $741.0 million in 2023[414]. - Cash, cash equivalents, and restricted cash at the end of 2024 were $344.067 million, down from $359.284 million at the end of 2023[424]. - Inventory increased to $83.1 million as of December 31, 2024, up from $73.7 million in 2023, with purchased materials and work in progress contributing to the rise[481]. - Property and equipment, net decreased to $252.6 million as of December 31, 2024, from $279.6 million in 2023, with depreciation expense recorded at $33.9 million for the year[482]. Expenses - Total operating expenses decreased to $609.041 million in 2024 from $674.642 million in 2023, a reduction of approximately 9.7%[416]. - Stock-based compensation expense for 2024 was $140.749 million, compared to $166.950 million in 2023, indicating a decrease of about 15.7%[424]. - Research and development expenses were incurred for personnel, independent contractors, and laboratory supplies, with no specific dollar amount provided in the extracted content[455]. - Advertising costs increased to $3.9 million in 2024 from $3.3 million in 2023, while 2022 costs were $3.7 million[457]. Foreign Currency and Interest Rate Risks - Approximately 27% of sales in 2024 were denominated in currencies other than U.S. dollars, compared to 23% in 2023[397]. - A hypothetical 100 basis-point increase in interest rates would have adversely affected the fair value of the investment portfolio by approximately $0.2 million in 2024[396]. - The Company has exposure to foreign currency exchange risk, with a hypothetical 10% movement in exchange rates potentially changing cash and cash equivalents by approximately $4.2 million in 2024[398]. - The Company recognized foreign currency transaction losses of $2.1 million for the year ended December 31, 2024, compared to gains of $1.2 million and $0.2 million for the years ended December 31, 2023 and 2022, respectively[463]. Legal Matters - A jury awarded the Company more than $31 million in damages from NanoString, consisting of approximately $25 million in lost profits and approximately $6 million in royalties[518]. - NanoString filed a lawsuit against the Company alleging infringement of U.S. Patent No. 11,473,142, seeking injunctive relief and unspecified damages[523]. - The Munich Regional Court found that NanoString's CosMx products infringe EP Patent No. 2794928B1, issuing a permanent injunction effective June 1, 2023[525]. - The Company filed requests for preliminary injunctions in the Unified Patent Court alleging infringement of EP Patents 928 and 782, with the UPC granting the injunction for EP782 on September 19, 2023[527]. - The trial for the NanoString action is scheduled for November 2024, with discovery currently in progress[523]. - The Company filed a lawsuit against Vizgen alleging infringement of multiple U.S. Patents, with discovery ongoing and a Markman hearing held on January 10, 2024[530]. Stock and Equity - The Company has authorized the issuance of 1,200,000,000 shares of capital stock, including 1,000,000,000 shares of Class A common stock[540]. - As of December 31, 2024, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan was 1,842,338[542]. - The total intrinsic value of stock options exercised was $12.3 million for the year ended December 31, 2024, compared to $78.0 million in 2023 and $89.5 million in 2022[546]. - The total unrecognized stock-based compensation related to stock options as of December 31, 2024, was $19.5 million, expected to be recognized over approximately two years[546]. - The total unrecognized stock-based compensation related to restricted stock units (RSUs) was $194.4 million as of December 31, 2024, to be recognized over approximately three years[548]. - A total of 385,967 shares of Class A common stock were issued under the ESPP for the year ended December 31, 2024[559]. - The maximum number of shares available under the ESPP is 3,686,671, with 2,705,096 shares available for issuance as of December 31, 2024[559]. Tax Positions - The provision for income taxes for the year ended December 31, 2024, was $4.927 million, a decrease from $6.336 million in 2023[494]. - The company’s total deferred tax assets were $496.171 million as of December 31, 2024, with a full valuation allowance maintained on U.S. net deferred tax assets[496]. - The total amount of unrecognized gross tax benefits was $50.0 million as of December 31, 2024, compared to $45.7 million in 2023, with $2.9 million and $2.7 million potentially affecting the effective tax rate if recognized[500]. Commitments and Contingencies - The Company has commitments to make a total of $13.2 million in purchases over the next year as of December 31, 2024[507]. - The Company has entered into non-cancelable arrangements for subscription software services totaling $19.6 million over the next five years[508]. - The Company incurred operating lease costs of $12.6 million, $13.6 million, and $13.1 million for the years ended December 31, 2024, 2023, and 2022, respectively[513]. - The total lease payments due under the Company's operating lease liabilities as of December 31, 2024, amount to $101.2 million[514].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ______________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) Delaware 001-39035 45-5614458 (Commission File Number) (IRS Employer Identification No.) Washington, D.C. 20549 ______________________ 6230 Stoneridge Mall R ...

PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025.Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023. In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Geno ...

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158.14 million, down 14% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces ...

Core Insights - The Chan Zuckerberg Initiative (CZI) has launched the Billion Cells Project to create a dataset of one billion cells aimed at enhancing AI model development in biology [1][2] - The project will provide critical data for understanding cellular behavior, gene function, and the genetic drivers of human diseases, ultimately guiding drug development [5][6] Project Overview - The Billion Cells Project is a collaboration involving CZI, 10x Genomics, Ultima Genomics, and leading researchers, focusing on generating data at an unprecedented scale [1][4] - The initiative aims to produce a cohesive dataset that will improve the training of AI models and facilitate transformative discoveries in precision medicine and functional genomics [2][3] Technological Innovations - The project will utilize 10x Genomics' Chromium GEM-X technology, which enhances sensitivity, throughput, and data quality for single-cell analysis [5][6] - Sequencing will be conducted on Ultima Genomics' UG 100™ platform, known for its ultra-high throughput and low-cost capabilities, making it suitable for large-scale genomic data generation [6][8] Collaboration and Impact - CZI's approach emphasizes collaboration among industry partners to accelerate data generation and knowledge sharing across various biological domains [4][8] - The project is expected to set a precedent for future collaborations in the life sciences sector, aiming to deliver significant advancements in understanding human biology [8]

Torex Gold Provides Q4 2024 Update on Media Luna ProjectConstruction substantially complete and first copper concentrate on track for MarchFebruary 04, 2025 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q4 2024 update on the development of its Media Luna Project ("Media Luna"). Unless otherwise stated, ...

PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release ...